NASDAQ:MOR MorphoSys (MOR) Stock Price, News & Analysis $18.96 0.00 (0.00%) (As of 10/30/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About MorphoSys Stock (NASDAQ:MOR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MorphoSys alerts:Sign Up Key Stats Today's Range$18.96▼$18.9650-Day Range$18.96▼$18.9652-Week Range$4.18▼$19.50VolumeN/AAverage Volume1.02 million shsMarket Capitalization$2.86 billionP/E RatioN/ADividend YieldN/APrice Target$11.78Consensus RatingHold Company OverviewMorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. MorphoSys Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks3rd Percentile Overall ScoreMOR MarketRank™: MorphoSys scored higher than 3% of companies evaluated by MarketBeat, and ranked 986th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingMorphoSys has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageMorphoSys has received no research coverage in the past 90 days.Read more about MorphoSys' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MorphoSys are expected to grow in the coming year, from ($2.42) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MorphoSys is -5.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MorphoSys is -5.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMorphoSys has a P/B Ratio of 54.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MOR. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMorphoSys does not currently pay a dividend.Dividend GrowthMorphoSys does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for MOR. News and Social Media1.4 / 5News SentimentN/A News SentimentMorphoSys has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MorphoSys insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.05% of the stock of MorphoSys is held by insiders.Percentage Held by InstitutionsOnly 18.38% of the stock of MorphoSys is held by institutions.Read more about MorphoSys' insider trading history. Receive MOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter. Email Address MOR Stock News HeadlinesMyrobalan Therapeutics Strengthens Board of Directors with Appointment of Emma ReeveOctober 16, 2024 | finance.yahoo.comBiogen: Felzartamab Receives Breakthrough Therapy Designation - Quick FactsOctober 9, 2024 | markets.businessinsider.comAlgo Trading Is Here 🔥One trade alert each day backed by powerful technology, yours free. For $0 you can get access to one daily stock picked directly from StocksToTrade’s algo-powered system.October 31, 2024 | Timothy Sykes (Ad)Novartis Stock: Resilient Performance Amid Market VolatilityOctober 8, 2024 | finanznachrichten.deEnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategySeptember 26, 2024 | tmcnet.comNovartis Pharma AG: FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancerSeptember 17, 2024 | finanznachrichten.deMorphoSys AG: Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General MeetingAugust 27, 2024 | finanznachrichten.deEQS-News: Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General MeetingAugust 27, 2024 | markets.businessinsider.comSee More Headlines MOR Stock Analysis - Frequently Asked Questions How have MOR shares performed this year? MorphoSys' stock was trading at $9.90 at the beginning of 2024. Since then, MOR stock has increased by 91.5% and is now trading at $18.96. View the best growth stocks for 2024 here. When did MorphoSys IPO? MorphoSys (MOR) raised $200 million in an IPO on Thursday, April 19th 2018. The company issued 8,300,000 shares at a price of $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers. Who are MorphoSys' major shareholders? MorphoSys' top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.08%) and GAMMA Investing LLC. How do I buy shares of MorphoSys? Shares of MOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of MorphoSys own? Based on aggregate information from My MarketBeat watchlists, some other companies that MorphoSys investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), e.l.f. Beauty (ELF), EMCOR Group (EME), Disc Medicine (IRON) and Builders FirstSource (BLDR). Company Calendar Today10/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MOR CUSIPN/A CIK1340243 Webwww.morphosys.com Phone(498) 989-9270Fax49-89-8992-7222Employees730Year FoundedN/APrice Target and Rating Average Stock Price Target$11.78 High Stock Price Target$18.25 Low Stock Price Target$4.75 Potential Upside/Downside-37.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-205,350,000.00 Net Margins-226.79% Pretax Margin-225.77% Return on Equity-694.31% Return on Assets-22.55% Debt Debt-to-Equity Ratio4.98 Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual Sales$238.28 million Price / Sales11.99 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book54.17Miscellaneous Outstanding Shares150,621,000Free Float150,546,000Market Cap$2.86 billion OptionableNot Optionable Beta1.20 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NASDAQ:MOR) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.